Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021


CAMBRIDGE, Mass. and BOULDER, Colo., July 27, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, from 10:55 -11:25am ET.

Access to the webcast of this event, as well as an archived recording, will be available under the "Events" tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events.

About Cogent Biosciences, Inc. 
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the newly formed Cogent Research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. Cogent Biosciences is based in Cambridge, MA and Boulder, Co. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

SOURCE Cogent Biosciences, Inc.


These press releases may also interest you

at 22:03
Contract Research Organization Services Market Projected to Reach $184.21 billion by 2030 - Exclusive Report by 360iResearch
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

at 21:30
GREENBROOK TMS REPORTS FISCAL YEAR 2023 OPERATIONAL AND FINANCIAL RESULTS
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

at 20:25
AHF Praises Colombia for Putting Lives Before Pharma Greed
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC Deputy Registrar, Kathy Lauriente, honoured with Distinguished Service Award from Thompson Rivers University (TRU)
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT Expands to Meet the Growing Need for Self-Harm, Suicidal Thoughts, and Depression Therapy.
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
Notice - NOVA TECH LTD and CYNTHIA PETION, File No. 2023-20
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

More news about Health...


News published on and distributed by: